AU2017250431B2 - 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors - Google Patents

1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors Download PDF

Info

Publication number
AU2017250431B2
AU2017250431B2 AU2017250431A AU2017250431A AU2017250431B2 AU 2017250431 B2 AU2017250431 B2 AU 2017250431B2 AU 2017250431 A AU2017250431 A AU 2017250431A AU 2017250431 A AU2017250431 A AU 2017250431A AU 2017250431 B2 AU2017250431 B2 AU 2017250431B2
Authority
AU
Australia
Prior art keywords
methyl
pyrazolo
pyridin
compound
tetrahydropyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017250431A
Other languages
English (en)
Other versions
AU2017250431A1 (en
Inventor
Mikkel JESSING
Karsten Juhl
Jan Kehler
Morten LANGGÅRD
Mauro Marigo
Lars Kyhn Rasmussen
Paulo Jorge Vieira Vital
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2017250431A1 publication Critical patent/AU2017250431A1/en
Application granted granted Critical
Publication of AU2017250431B2 publication Critical patent/AU2017250431B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017250431A 2016-04-12 2017-04-07 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors Ceased AU2017250431B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600221 2016-04-12
DKPA201600221 2016-04-12
PCT/EP2017/058332 WO2017178350A1 (en) 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors

Publications (2)

Publication Number Publication Date
AU2017250431A1 AU2017250431A1 (en) 2018-10-11
AU2017250431B2 true AU2017250431B2 (en) 2020-07-16

Family

ID=58489694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017250431A Ceased AU2017250431B2 (en) 2016-04-12 2017-04-07 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors

Country Status (43)

Country Link
US (3) US20170291901A1 (enExample)
EP (1) EP3442975B1 (enExample)
JP (1) JP7093306B2 (enExample)
KR (1) KR20180133413A (enExample)
CN (1) CN109071549B (enExample)
AR (1) AR108109A1 (enExample)
AU (1) AU2017250431B2 (enExample)
BR (1) BR112017026278A2 (enExample)
CA (1) CA3020053A1 (enExample)
CL (1) CL2018002881A1 (enExample)
CO (1) CO2018010323A2 (enExample)
CR (1) CR20180470A (enExample)
CY (1) CY1123269T1 (enExample)
DK (1) DK3442975T3 (enExample)
DO (1) DOP2018000201A (enExample)
EA (1) EA035197B1 (enExample)
EC (1) ECSP18074641A (enExample)
ES (1) ES2814289T3 (enExample)
GE (1) GEP20207057B (enExample)
HR (1) HRP20201331T1 (enExample)
HU (1) HUE050320T2 (enExample)
IL (1) IL262257B (enExample)
LT (1) LT3442975T (enExample)
MA (1) MA44656B1 (enExample)
ME (1) ME03820B (enExample)
MX (1) MX374251B (enExample)
MY (1) MY194722A (enExample)
NI (1) NI201800092A (enExample)
PE (1) PE20181853A1 (enExample)
PH (1) PH12018502168A1 (enExample)
PL (1) PL3442975T3 (enExample)
PT (1) PT3442975T (enExample)
RS (1) RS60714B1 (enExample)
RU (1) RU2018133391A (enExample)
SG (1) SG11201808221QA (enExample)
SI (1) SI3442975T1 (enExample)
SM (1) SMT202000446T1 (enExample)
SV (1) SV2018005753A (enExample)
TN (1) TN2018000321A1 (enExample)
TW (1) TWI729109B (enExample)
UA (1) UA121925C2 (enExample)
WO (1) WO2017178350A1 (enExample)
ZA (1) ZA201806407B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
CA3120971A1 (en) * 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
CN112189013A (zh) 2018-05-25 2021-01-05 细胞内治疗公司 有机化合物
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) * 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
WO2004018474A1 (de) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Phenyl-substituierte pyrazolopyrimidine
WO2004026876A1 (de) * 2002-08-23 2004-04-01 Bayer Healthcare Ag Alkyl-substituierte pyrazolopyrimidine
WO2004099211A1 (de) * 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
WO2008139293A1 (en) * 2007-05-11 2008-11-20 Pfizer Inc. Amino-heterocyclic compounds
EP2305262A1 (de) * 2002-08-23 2011-04-06 Boehringer Ingelheim International GmbH Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
KR20110098731A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP5879336B2 (ja) * 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2012040230A1 (en) 2010-09-20 2012-03-29 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
CN104703987B (zh) 2011-10-10 2017-05-03 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
SG11201403909RA (en) 2012-01-26 2014-10-30 Lundbeck & Co As H Pde9 inhibitors with imidazo triazinone backbone
CA2877149C (en) 2012-06-18 2021-01-19 Dart Neuroscience (Cayman) Ltd Substituted pyridine azolopyrimidine-5-(6h)-one compounds
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
TW201609713A (zh) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) * 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
TW201639851A (zh) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) * 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
WO2004018474A1 (de) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Phenyl-substituierte pyrazolopyrimidine
WO2004026876A1 (de) * 2002-08-23 2004-04-01 Bayer Healthcare Ag Alkyl-substituierte pyrazolopyrimidine
EP2305262A1 (de) * 2002-08-23 2011-04-06 Boehringer Ingelheim International GmbH Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004099211A1 (de) * 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
WO2008139293A1 (en) * 2007-05-11 2008-11-20 Pfizer Inc. Amino-heterocyclic compounds

Also Published As

Publication number Publication date
RU2018133391A3 (enExample) 2020-06-23
EA035197B1 (ru) 2020-05-14
HRP20201331T1 (hr) 2020-11-27
MA44656A (fr) 2019-02-20
GEP20207057B (en) 2020-01-27
DK3442975T3 (da) 2020-08-24
ME03820B (me) 2021-04-20
PE20181853A1 (es) 2018-12-03
JP2019517996A (ja) 2019-06-27
IL262257A (en) 2018-11-29
AR108109A1 (es) 2018-07-18
SG11201808221QA (en) 2018-10-30
JP7093306B2 (ja) 2022-06-29
MY194722A (en) 2022-12-15
TN2018000321A1 (en) 2020-01-16
TWI729109B (zh) 2021-06-01
TW201738242A (zh) 2017-11-01
EP3442975B1 (en) 2020-07-29
CO2018010323A2 (es) 2018-12-14
CY1123269T1 (el) 2021-12-31
PL3442975T3 (pl) 2020-11-16
ZA201806407B (en) 2019-12-18
US11104680B2 (en) 2021-08-31
RU2018133391A (ru) 2020-05-12
MX374251B (es) 2025-03-05
EP3442975A1 (en) 2019-02-20
KR20180133413A (ko) 2018-12-14
US20190194204A1 (en) 2019-06-27
CN109071549A (zh) 2018-12-21
US20200102316A1 (en) 2020-04-02
SI3442975T1 (sl) 2020-10-30
US10538525B2 (en) 2020-01-21
US20170291901A1 (en) 2017-10-12
AU2017250431A1 (en) 2018-10-11
CR20180470A (es) 2018-12-21
ES2814289T3 (es) 2021-03-26
ECSP18074641A (es) 2018-10-31
NI201800092A (es) 2019-03-14
LT3442975T (lt) 2020-09-25
EA201891897A1 (ru) 2019-03-29
CL2018002881A1 (es) 2018-12-14
IL262257B (en) 2020-11-30
MA44656B1 (fr) 2020-10-28
PT3442975T (pt) 2020-09-03
BR112017026278A2 (pt) 2018-09-11
RS60714B1 (sr) 2020-09-30
UA121925C2 (uk) 2020-08-10
PH12018502168A1 (en) 2019-08-19
CA3020053A1 (en) 2017-10-19
DOP2018000201A (es) 2018-11-15
HUE050320T2 (hu) 2020-11-30
SMT202000446T1 (it) 2020-09-10
MX2018012496A (es) 2019-02-21
WO2017178350A1 (en) 2017-10-19
SV2018005753A (es) 2018-11-27
CN109071549B (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
AU2017250431B2 (en) 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors
AU2016256573B2 (en) Imidazopyrazinones as PDE1 inhibitors
US10905688B2 (en) Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
EP3529250A1 (en) Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
US11535611B2 (en) Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US10774086B2 (en) GSK-3 inhibitors
HK40001748B (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
HK40001748A (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途
OA18771A (en) Imidazopyrazinones as PDE1 Inhibitors
HK1096401B (en) Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives
HK1096401A1 (en) Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired